Healio (7/28, Volansky) reported that the FDA approved “an over-the-counter, nonprescription RiVive (naloxone hydrochloride) nasal spray for emergency treatment of opioid overdose.” This marks “the second nonprescription naloxone product approved by the FDA.”
Reuters (7/28) reported that the manufacturer Harm Reduction “said it anticipates that RiVive will be available early next year, primarily to harm-reduction organizations and state governments.” The not-for-profit drugmaker also “said it would make at least 200,000 doses available for free.”
The Hill (7/28, Weixel) and Pharmacy Times (7/28) also reported.
Related Links:
— “FDA approves nonprescription nasal spray for opioid overdose,”Rob Volansky, Healio, July 28, 2023